Case report: Giant lymph node metastases: a new opportunity for cancer radioimmunotherapy?

Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considere...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1357601
Main Authors Bian, Yuan, Zhang, Zhenhua, Deng, Xiangyu, Wen, Qinglian, Li, Dan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness. In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months. The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.
AbstractList BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.Case presentationIn this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.ConclusionsThe combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.
Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.Case presentationIn this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.ConclusionsThe combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.
Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness. In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months. The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.
Author Li, Dan
Bian, Yuan
Zhang, Zhenhua
Deng, Xiangyu
Wen, Qinglian
AuthorAffiliation 2 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan , China
1 Department of Oncology, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan , China
AuthorAffiliation_xml – name: 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan , China
– name: 2 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan , China
Author_xml – sequence: 1
  givenname: Yuan
  surname: Bian
  fullname: Bian, Yuan
– sequence: 2
  givenname: Zhenhua
  surname: Zhang
  fullname: Zhang, Zhenhua
– sequence: 3
  givenname: Xiangyu
  surname: Deng
  fullname: Deng, Xiangyu
– sequence: 4
  givenname: Qinglian
  surname: Wen
  fullname: Wen, Qinglian
– sequence: 5
  givenname: Dan
  surname: Li
  fullname: Li, Dan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38348039$$D View this record in MEDLINE/PubMed
BookMark eNpVkk9v1DAQxS1URMvSL8AB-chlF_9LnPRSoRWUSpW4wIWLNbHH3VSJHewEtN8eb3epWsvSjOyf3rPG7y05CzEgIe8520jZtJ98P47LRjChNlxWumb8Fbngda3WUgh19qw_J5c5P7CyVCulrN6Qc9lI1TDZXpBfW8hIE04xzVf0pocw02E_TjsaokM64gy5bMxXFGjAvzROB3QJ_bynPiZqIVhMNIHr4-FJIc47TDDtr9-R1x6GjJenuiI_v375sf22vvt-c7v9fLe2SrB5rXWHsmuVrhVjnXLSIkrNRd35BhzwGphSbWdrjt568BwKwkoVrvJOd3JFbo-6LsKDmVI_QtqbCL15PIjp3kCaezug4a7ToMpMGu9VVVwb1YrK2sZJ3fIykRW5PmpNSzeisxjmBMML0Zc3od-Z-_jHcNZUbSV0Ufh4Ukjx94J5NmOfLQ4DBIxLNqIVNdO61rygH56bPbn8_50CiCNgU8w5oX9CODOHFJjHFJhDCswpBfIf_uCnrQ
Cites_doi 10.1001/jama.2017.11470
10.6004/jnccn.2015.0055
10.1111/his.13723
10.4161/onci.28518
10.1136/jitc-2020-002038
10.1056/NEJMoa1309748
10.1038/modpathol.2015.108
10.1016/j.radonc.2018.03.003
10.1016/j.cell.2023.02.021
10.1016/j.ygyno.2012.12.035
10.1097/PAS.0000000000001506
10.1016/S0140-6736(17)31607-0
10.1016/j.ijrobp.2012.01.070
10.1016/j.cell.2018.09.035
10.1136/ijgc-2023-004705
10.1146/annurev-immunol-042718-041717
10.1186/s13045-017-0541-9
10.1200/JCO.18.01265
10.1016/j.cell.2016.12.022
10.1158/2326-6066.CIR-14-0196
10.1038/modpathol.2016.221
10.1038/s41379-019-0433-3
10.3322/caac.21660
10.1200/JCO.2017.74.5471
10.1158/1078-0432.CCR-14-2824
10.1056/NEJMoa1613210
10.1016/S1470-2045(15)70004-5
10.1158/1078-0432.CCR-20-0776
10.1200/JCO.2022.40.16_suppl.5528
10.1001/jamaoncol.2019.3857
10.1126/sciimmunol.abg3551
10.3802/jgo.2016.27.e43
10.1186/s13045-021-01045-x
10.1016/j.cell.2022.04.019
10.1038/s41467-023-39383-8
10.1002/ijgo.13865
10.1016/j.semcdb.2014.10.002
10.1016/S1470-2045(23)00411-4
10.1016/j.cell.2008.07.001
10.1200/JCO.19.00739
ContentType Journal Article
Copyright Copyright © 2024 Bian, Zhang, Deng, Wen and Li.
Copyright © 2024 Bian, Zhang, Deng, Wen and Li 2024 Bian, Zhang, Deng, Wen and Li
Copyright_xml – notice: Copyright © 2024 Bian, Zhang, Deng, Wen and Li.
– notice: Copyright © 2024 Bian, Zhang, Deng, Wen and Li 2024 Bian, Zhang, Deng, Wen and Li
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2024.1357601
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_1db7a42248ff453b984925cc8d379180
PMC10859527
38348039
10_3389_fimmu_2024_1357601
Genre Case Reports
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c420t-77be3b9476400b4d3cee37126bf8ada16a0449bc61efcfaf1ad3c0af12d5fd7b3
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:29:42 EDT 2025
Thu Aug 21 18:35:16 EDT 2025
Fri Jul 11 09:40:27 EDT 2025
Mon Jul 21 05:58:01 EDT 2025
Tue Jul 01 03:33:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords radiotherapy
case report
cervical cancer
immunotherapy
lymph node metastasis
Language English
License Copyright © 2024 Bian, Zhang, Deng, Wen and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-77be3b9476400b4d3cee37126bf8ada16a0449bc61efcfaf1ad3c0af12d5fd7b3
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Christopher Hillyar, University of Oxford, United Kingdom
Edited by: Ming Yi, Zhejiang University, China
These authors have contributed equally to this work and share first authorship
Reviewed by: Tianye Li, Zhejiang University School of Medicine, China
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2024.1357601
PMID 38348039
PQID 2926077671
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_1db7a42248ff453b984925cc8d379180
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10859527
proquest_miscellaneous_2926077671
pubmed_primary_38348039
crossref_primary_10_3389_fimmu_2024_1357601
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-00-00
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – year: 2024
  text: 2024-00-00
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2024
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Naumann (B28) 2019; 37
Koh (B8) 2015; 13
Rodrigues (B39) 2023; 14
Mezache (B14) 2015; 28
Sakaguchi (B34) 2020; 38
Li (B2) 2016; 27
Kim (B4) 2012; 84
Demaria (B40) 2021; 9
Sharabi (B38) 2015; 3
Tewari (B11) 2017; 390
Bhatla (B6) 2021
Golden (B36) 2014; 3
Curley (B18) 2020; 33
Dibbern (B15) 2020; 44
Tewari (B9) 2014; 370
Chung (B19) 2019; 37
Massague (B24) 2008; 134
Spitzer (B35) 2017; 168
Sung (B1) 2021; 71
Rahim (B5) 2023; 186
Leath (B7) 2013; 129
Chinn (B17) 2019; 74
Gao (B23) 2023; 24
Sanmamed (B13) 2018; 175
Filatenkov (B37) 2015; 21
Reticker-Flynn (B33) 2022; 185
Liu (B12) 2017; 10
Frenel (B27) 2017; 35
Yi (B25) 2021; 14
Oaknin (B26) 2022; 40
du Bois (B31) 2021; 6
Penson (B10) 2015; 16
Nathanson (B32) 2015; 38
Giuliano (B30) 2017; 318
Xia (B20) 2023; 33
Enwere (B16) 2017; 30
Da Silva (B21) 2020; 26
Cibula (B3) 2018; 127
Mayadev (B22) 2020; 6
Faries (B29) 2017; 376
References_xml – volume: 318
  year: 2017
  ident: B30
  article-title: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2017.11470
– volume: 13
  start-page: 395
  year: 2015
  ident: B8
  article-title: Cervical cancer, version 2.2015
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2015.0055
– volume: 74
  year: 2019
  ident: B17
  article-title: PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy
  publication-title: Histopathology
  doi: 10.1111/his.13723
– volume: 3
  year: 2014
  ident: B36
  article-title: Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
  publication-title: Oncoimmunology
  doi: 10.4161/onci.28518
– volume: 9
  year: 2021
  ident: B40
  article-title: Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-002038
– volume: 370
  year: 2014
  ident: B9
  article-title: Improved survival with bevacizumab in advanced cervical cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1309748
– volume: 28
  year: 2015
  ident: B14
  article-title: Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2015.108
– volume: 127
  year: 2018
  ident: B3
  article-title: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2018.03.003
– volume: 186
  start-page: 1127
  year: 2023
  ident: B5
  article-title: Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
  publication-title: Cell
  doi: 10.1016/j.cell.2023.02.021
– volume: 129
  year: 2013
  ident: B7
  article-title: 3rd, Straughn JM, Jr.: Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2012.12.035
– volume: 44
  year: 2020
  ident: B15
  article-title: Loss of MHC class I expression in HPV-associated cervical and vulvar neoplasia: A potential mechanism of resistance to checkpoint inhibition
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001506
– volume: 390
  year: 2017
  ident: B11
  article-title: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)31607-0
– volume: 84
  year: 2012
  ident: B4
  article-title: Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2012.01.070
– volume: 175
  year: 2018
  ident: B13
  article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.035
– volume: 33
  year: 2023
  ident: B20
  article-title: Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
  publication-title: Int J Gynecol Cancer
  doi: 10.1136/ijgc-2023-004705
– volume: 38
  year: 2020
  ident: B34
  article-title: Regulatory T cells and human disease
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-042718-041717
– volume: 10
  start-page: 174
  year: 2017
  ident: B12
  article-title: Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0541-9
– volume: 37
  year: 2019
  ident: B19
  article-title: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.01265
– volume: 168
  start-page: 487
  year: 2017
  ident: B35
  article-title: Systemic immunity is required for effective cancer immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2016.12.022
– volume: 3
  year: 2015
  ident: B38
  article-title: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0196
– volume: 30
  year: 2017
  ident: B16
  article-title: Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2016.221
– volume: 33
  year: 2020
  ident: B18
  article-title: Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia
  publication-title: Mod Pathol
  doi: 10.1038/s41379-019-0433-3
– volume: 71
  year: 2021
  ident: B1
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 35
  year: 2017
  ident: B27
  article-title: Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase ib KEYNOTE-028 trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.74.5471
– volume: 21
  year: 2015
  ident: B37
  article-title: Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-2824
– volume: 376
  year: 2017
  ident: B29
  article-title: Completion dissection or observation for sentinel-node metastasis in melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1613210
– volume: 16
  year: 2015
  ident: B10
  article-title: Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)70004-5
– volume: 26
  year: 2020
  ident: B21
  article-title: Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0776
– volume: 40
  year: 2022
  ident: B26
  article-title: Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2022.40.16_suppl.5528
– volume: 6
  year: 2020
  ident: B22
  article-title: Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.3857
– volume: 6
  year: 2021
  ident: B31
  article-title: Tumor-draining lymph nodes: At the crossroads of metastasis and immunity
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abg3551
– volume: 27
  year: 2016
  ident: B2
  article-title: Advances in diagnosis and treatment of metastatic cervical cancer
  publication-title: J Gynecol Oncol
  doi: 10.3802/jgo.2016.27.e43
– volume: 14
  start-page: 27
  year: 2021
  ident: B25
  article-title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-beta and PD-L1
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01045-x
– volume: 185
  start-page: 1924
  year: 2022
  ident: B33
  article-title: Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
  publication-title: Cell
  doi: 10.1016/j.cell.2022.04.019
– volume: 14
  start-page: 3698
  year: 2023
  ident: B39
  article-title: Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-39383-8
– start-page: 28
  year: 2021
  ident: B6
  article-title: Cancer of the cervix uteri: 2021 update
  publication-title: Int J Gynaecol Obstet
  doi: 10.1002/ijgo.13865
– volume: 38
  year: 2015
  ident: B32
  article-title: Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression
  publication-title: Semin Cell Dev Biol
  doi: 10.1016/j.semcdb.2014.10.002
– volume: 24
  year: 2023
  ident: B23
  article-title: Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(23)00411-4
– volume: 134
  year: 2008
  ident: B24
  article-title: TGFbeta in cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2008.07.001
– volume: 37
  year: 2019
  ident: B28
  article-title: Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkMate 358 trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00739
SSID ssj0000493335
Score 2.3578608
Snippet Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a...
BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1357601
SubjectTerms case report
cervical cancer
Immunology
immunotherapy
lymph node metastasis
radiotherapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1dS-QwFA0iLPiy6Lofo-sSYd-WYtuk-fBlUVkVQZ8UZF9CPtkRpx1mOg_z771JqszIgi8-FdrQpuc03HPT5FyEfgovDITFsmgkc0V0wCpMzUNBrCa147xkaR_39Q27vKNX9839SqmvuCYs2wNn4I4qZ7imEGhECLQhRopop2etcITLSqRsHWLeSjL1kHUvIaTJu2QgC5NHYTyZLCAfrGks9RBXgqxFomTY_z-V-Xqx5Er0Od9GHwfZiE9yd3fQhm8_oQ-5kORyF_09g2CE8_z_Mb4Aynv8uASicNs5jye-16AC535-jDUGIY27aWy6gPG8xCBbsY3kz_BMu3EXX6EdNmYtf39Gd-d_bs8ui6FqQmFpXfYgl40HmChnMDwNdQTCIOFVzUwQ2umK6ZJSaSyrfLBBh0pDkxKOtWuC44Z8QZtt1_pvCCcaoz9PcBSEnZcW7sAto0ybIJkfoV_PCKppNsdQkFREvFXCW0W81YD3CJ1GkF9aRmPrdALoVgPd6i26R-jwmSIFAyH-3dCt7xZzVUtIzaI3ETzoa6bs5VGQhlNREjlCYo3Mtb6sX2nH_5LZdpUc4Gq-9x6930dbEZE8hfMdbfazhT8AUdObH-n7fQJB4_WY
  priority: 102
  providerName: Directory of Open Access Journals
Title Case report: Giant lymph node metastases: a new opportunity for cancer radioimmunotherapy?
URI https://www.ncbi.nlm.nih.gov/pubmed/38348039
https://www.proquest.com/docview/2926077671
https://pubmed.ncbi.nlm.nih.gov/PMC10859527
https://doaj.org/article/1db7a42248ff453b984925cc8d379180
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA_nieCL-O36cUTwTaptkybpgRx6eHcI55MLiy8hn7py257dLtj_3pm0e7hyvvnSQps2yUyG-U0-fkPIKxWUBbeYZ1UtfIYMWJktZcyYM6z0UuYineM-_yzO5vzTolrskW26o0mA62tDO8wnNe8u3vz6ORyBwb_DiBP87du4XK02EOqVHLM44CaPG-QmeCaJGQ3OJ7j_Y0TDjLFqPDvzj093_FOi8b8Oe_69hfIPn3Ryl9yZwCR9P2r_HtkLzX1ya0wvOTwgX4_BRdFxVeCQnsJA6OnFAOqjTesDXYXeADZch_UhNRTgNW0vsegGrHygAGapwyHR0c74ZYtdaKbjWsPRQzI_-fjl-Cybcilkjpd5DyDaBmZrLgUYreWegXNksiiFjcp4UwiTc15bJ4oQXTSxMFAkh3vpq-ilZY_IftM24QmhSbnI2hM9B7gXagd_kE5wYWysRZiR11sJ6suRMkNDqIHy1kneGuWtJ3nPyAcU8lVJpLtOD9rum56sRxfeSsMBbagYeQX9UMip6JzyTNaFymfk5VZFGswD1zxME9rNWpc1BGzIWAQVPR5VdlUVBOdc5ayeEbWjzJ227L5plt8TBXeReOFK-fR_tP4ZuY0SGSd2npP9vtuEFwB1enuQpgjgerooDtJY_g1a2QCZ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Case+report%3A+Giant+lymph+node+metastases%3A+a+new+opportunity+for+cancer+radioimmunotherapy%3F&rft.jtitle=Frontiers+in+immunology&rft.au=Yuan+Bian&rft.au=Zhenhua+Zhang&rft.au=Xiangyu+Deng&rft.au=Qinglian+Wen&rft.date=2024&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1357601&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1db7a42248ff453b984925cc8d379180
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon